Revolution Medicines Stock (NASDAQ: RVMD)

Revolution Medicines

REVOLUTION MEDICINES INC

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Milan,,Italy,-,August,10,,2017:,Groupon,Website,Homepage.,It.

News

Intraday Update

Markets

Movers

Trading Ideas

ALVO

AXON

CVNA

DAVE

EPAM

GRPN

MELI

PAYC

QBTS

QDEL

RVMD

SEZL

STKL

VTRS

Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday

Biotech

Health Care

General

Revolution Medicines shared Phase 1 data showing zoldonrasib&#39;s acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025.

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

Healthcare Costs

Long Ideas

Pre-Market Outlook

ELAN

Top 3 Health Care Stocks That Could Blast Off In December

Revolution Medicines, Inc. - Common Stock

Revolution Medicines Inc

Press Releases

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Revolution Medicines to Participate in March 2025 Investor Conferences

Earnings

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to Participate in April 2025 Investor Conferences

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Barbara Weber, M.D., Elected to ITM Supervisory Board

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

BNTX

RLAY

TNGX

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

HC Wainwright & Co.

Oppenheimer

Guggenheim

Needham

Wedbush

Comments

Revolution Medicines

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell